Information Provided By:
Fly News Breaks for October 19, 2018
PACB
Oct 19, 2018 | 07:57 EDT
Cowen analyst Doug Schenkel initiated Pacific Biosciences with an Outperform rating, stating that the company will be well positioned for a growth inflection following the launch of its 8M chip in 2019. He said the chip will compete at price and be comparable to others without compromising on its differentiated attributes. Schenkel has a $6.50 price target on Pacific Biosciences shares.
News For PACB From the Last 2 Days
PACB
PACB
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.